World Health Organization approves mpox vaccine for children

The World Health Organization (WHO) has taken a significant step in public health by authorizing the first mpox vaccine for children, a move that experts believe will enhance immunization efforts for one of the most vulnerable populations affected by the ongoing outbreaks in Africa. This decision comes at a time when cases among children in regions like Congo have surged alarmingly.

Rising mpox cases among children

According to recent reports from the charity Save the Children, cases of mpox among children under 18 in Congo have skyrocketed by over 130%. With more than 25,000 suspected cases now reported, the urgency for effective vaccination has never been clearer. Dr. Katia Vieira de Moraes LaCasse from Save the Children emphasized the heightened risk for children, stating, “Children are almost four times more likely than adults to die from the newest form of mpox, which was first identified in eastern Congo earlier this year.” This alarming statistic highlights the critical need for targeted health interventions.

Understanding mpox and its impact

Mpox, a disease related to smallpox, manifests through symptoms such as fever, rash, lesions, and fatigue. Children are particularly susceptible due to their exploratory nature; they often engage with their environment through touch and taste, making them more vulnerable to infections. Moreover, their immune systems are not as robust as those of adults, which further exacerbates their risk. The WHO’s approval of the mpox vaccine developed by KM Biologics for children over one year old is a crucial step in addressing this public health crisis.

Global response and future implications

Previously, the WHO had authorized the mpox vaccine from Bavarian Nordic for individuals aged 18 and older. However, the recent decision to include younger populations reflects a growing recognition of the need for comprehensive vaccination strategies. As of now, approximately 50,000 individuals in Congo have received the Bavarian Nordic vaccine, and Japan has pledged to donate around three million doses of the KM Biologics vaccine to aid in the fight against mpox. The WHO is also set to convene an expert committee to assess whether the outbreaks in Africa still constitute a global emergency.

As the situation evolves, it is imperative for health organizations and governments to prioritize the health of children, who are disproportionately affected by this outbreak. The introduction of the mpox vaccine for children could be a game-changer in controlling the spread of this disease and ultimately saving lives.